COVID-19 Update: We are committed to providing eye care in a safe environment for our patients and staff during these challenging times.

View our safety procedures video
Participation in all clinical trials is voluntary and patients may choose to withdraw from any study at any time. Most of our clinical trials are sponsored by the federally-funded National Institutes of Health (NIH) or pharmaceutical and biotechnology companies. ClinicalTrials.Gov lists these and other clinical trials.

Below is a listing of our studies that are currently enrolling new patients.

Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov

  • Wet AMD (Age Related Macular Degeneration)
    • OPTIC Sponsored by Adverum Biotechnologies
      ADVM-022 Intravitreal Gene Therapy for Wet AMD (OPTIC)
    • ALTISSIMO Sponsored by Graybug Vision
      A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD (ALTISSIMO)
    • PANDA Sponsored by Chengdu Kanghong
      Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-1)
    • MERLIN Sponsored by Novartis
      Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)
    • TENAYA Sponsored by Roche/Genentech
      A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
    • Kodiak Sciences
      Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
    • Regenexbio
      RGX-314 Gene Therapy for Neovascular AMD Trial
    • LUCERNE Sponsored by Roche/Genentech
      A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
    • ARCHWAY Sponsored by Roche/Genentech
      A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)
    • PORTAL Sponsored by Roche/Genentech
      Extension Study for the Port Delivery System With Ranibizumab (Portal)
    • DAZZLE Sponsored by Kodiak Sciences
      A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (DAZZLE)
  • Dry AMD (Age Related Macular Degeneration)
    • LIGHTSITE Sponsored by Lumithera
      The objectives of this study are to evaluate the safety and efficacy of intravitreous administration of Zimura when administered in subjects with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD)
    • OAKS Sponsored by APELLIS
      Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
    • Gemini Therapeutics
      A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD)
    • Gyroscope Therapeutics Sponsored by MedSpace
      To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
    • AIRM Sponsored by Astellas
      To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
    • GALLEGO Sponsored by Genentech
      A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (GALLEGO)
    • Boehringer Ingelheim Pharmaceuticals
      Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809
    • Ophthotech
      Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    • TOGA Sponsored by University of Virginia
      Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) (TOGA)
    • Lineage/Cellcure
      Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
    • EXPLORE Sponsored by MedSpace (Gyroscope Therapeutics)
      First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
  • Uveitis
    • HUMBOLDT Sponsored by Gilead
      Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis (Humboldt)
    • META MUST Sponsored by NEI/NIH
      Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (MERIT)
    • LUMINA Sponsored by Santen
      LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
    • MUST Network
      Adalimumab vs. Conventional Immunosuppression for Uveitis Trial (ADVISE)
  • Retinal Vein Occlusion
    • Orion Sponsored by Aerie
      Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
    • RAPTOR Sponsored by Novartis
      Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)
    • Raven Sponsored by Novartis
      Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)
  • Diabetic Macular Edema
    • DRCR.net
      DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (DRCR AC)
    • RHINE Sponsored by Roche/Genentech
      A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)
    • YOSEMITE Sponsored by Roche/Genentech
      A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
    • KESTREL Sponsored by Novartis
      Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KESTREL)
    • Pagoda Sponsored by Genentech
      This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)
  • Diabetic Retinopathy
    • GUARD Sponsored by Aldeyra
      The GUARD Trial – Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
  • Retinitis Pigmentosa
    • AGTC
      Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations